NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Early in the pandemic there was an unfounded directive from the French government suggesting that non-
Read Article
Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division. They could receive a $500 debit card from Cigna, with just one string attached: they would have to switch to a different medication, one preferred by the insurer
Read Article
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read Article
The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not. A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic immune-mediated inflammatory diseases (
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
A large patient cohort study suggests that the mean diagnostic delay (DD) in European axial spondyloarthritis (axSpA) patients is 7.4 years, moreso in women and younger patients.
An online survey of 2,652 patients from 13 countries (European Map of Axial Spondyloarthritis - EMAS)
Read Article
The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA). After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein
Read Article
Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.
From a total of 64 studies identified the reported mean delay in diagnosing
Read Article
Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally incrased by taking TNFi therapy.
From their large registry (n=13,489) they
Read Article
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
Read Article
Dr. Jack Cush serves up this week's news and articles from RheumNow.com.
Read Article
Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.
At week 24, 45% of patients receiving subcutaneous guselkumab every 4 weeks and 50% of those given the medication
Read Article
Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).
Safety data from 10,685 psoriasis, 2,523 PsA and
Read Article
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do
Read Article
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read Article
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read Article
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Data derived from the retrospective
Read Article
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
I interviewed Dr. Wang and below are his five
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
